5.7. The Possible Prognostic Impact of the DEK-NUP214 Fusion for AML Patients Receiving Intensive Antileukemic Treatment: Adverse Prognosis After Intensive Antileukemic Chemotherapy. The gene discussed is NUP214; the disease is acute myeloid leukemia.